Biocardia Net Receivables vs Non Current Assets Total Analysis
| BCDA Stock | USD 2.27 0.06 2.58% |
Biocardia financial indicator trend analysis is way more than just evaluating Biocardia prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biocardia is a good investment. Please check the relationship between Biocardia Net Receivables and its Non Current Assets Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.
Net Receivables vs Non Current Assets Total
Net Receivables vs Non Current Assets Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biocardia Net Receivables account and Non Current Assets Total. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Biocardia's Net Receivables and Non Current Assets Total is -0.24. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Biocardia, assuming nothing else is changed. The correlation between historical values of Biocardia's Net Receivables and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Biocardia are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Net Receivables i.e., Biocardia's Net Receivables and Non Current Assets Total go up and down completely randomly.
Correlation Coefficient | -0.24 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Net Receivables
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most indicators from Biocardia's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biocardia current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.At present, Biocardia's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 12.57, whereas Selling General Administrative is forecasted to decline to about 3.3 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 9K | 6K | 6.9K | 6.6K | Depreciation And Amortization | 640K | 82K | 84K | 79.8K |
Biocardia fundamental ratios Correlations
Click cells to compare fundamentals
Biocardia Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biocardia fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 7.7M | 23.4M | 15.7M | 9.8M | 3.0M | 2.8M | |
| Other Current Liab | 1.8M | 2.2M | 2.9M | 3.0M | 1.3M | 806.1K | |
| Total Current Liabilities | 4.0M | 4.2M | 3.7M | 3.6M | 3.6M | 3.8M | |
| Total Stockholder Equity | 2.4M | 19.2M | 10.4M | 4.9M | (1.6M) | (1.5M) | |
| Property Plant And Equipment Net | 1.2M | 712K | 2.1M | 1.9M | 1.4M | 744.1K | |
| Net Debt | (4.4M) | (20.8M) | (11.0M) | (5.7M) | 212K | 222.6K | |
| Retained Earnings | (101.1M) | (116.1M) | (128.7M) | (140.6M) | (152.2M) | (144.6M) | |
| Accounts Payable | 914K | 746K | 507K | 683K | 890K | 934.5K | |
| Cash | 5.6M | 21.4M | 12.9M | 7.4M | 1.1M | 1.0M | |
| Non Current Assets Total | 1.3M | 766K | 2.2M | 1.9M | 1.5M | 1.6M | |
| Cash And Short Term Investments | 5.6M | 21.4M | 12.9M | 7.4M | 1.1M | 1.0M | |
| Net Receivables | 274K | 147K | 850K | 201K | 63K | 59.9K | |
| Common Stock Total Equity | 38K | 43K | 7K | 16K | 18.4K | 17.5K | |
| Common Stock Shares Outstanding | 5.6M | 674.6K | 1.1M | 1.2M | 1.4M | 1.4M | |
| Liabilities And Stockholders Equity | 7.7M | 23.4M | 15.7M | 9.8M | 3.0M | 2.8M | |
| Non Current Liabilities Total | 1.3M | 2.7M | 1.6M | 1.3M | 982K | 630.9K | |
| Other Current Assets | 642K | 401K | 924K | 300K | 295K | 436.7K | |
| Other Stockholder Equity | 103.4M | 135.2M | 139.1M | 145.5M | 150.5M | 158.1M | |
| Total Liab | 5.3M | 4.2M | 5.3M | 4.9M | 4.6M | 4.8M | |
| Total Current Assets | 6.4M | 22.7M | 13.5M | 7.9M | 1.5M | 1.4M | |
| Common Stock | 7K | 16K | 17K | 20K | 24K | 22.8K | |
| Current Deferred Revenue | 732K | 1.4M | 1.5M | 965K | 759K | 750.8K | |
| Inventory | 4K | (850K) | 1.0 | (201K) | (180.9K) | (171.9K) | |
| Net Tangible Assets | 2.4M | 19.2M | 10.4M | 4.9M | 5.6M | 5.5M | |
| Retained Earnings Total Equity | (72.5M) | (86.4M) | (101.1M) | (116.1M) | (104.5M) | (99.2M) | |
| Capital Surpluse | 83.5M | 90.1M | 103.4M | 135.2M | 155.5M | 163.3M | |
| Property Plant Equipment | 1.2M | 712K | 2.1M | 1.8M | 2.0M | 2.1M | |
| Net Invested Capital | 2.4M | 19.2M | 10.4M | 4.9M | (1.6M) | (1.5M) | |
| Net Working Capital | 2.4M | 18.4M | 9.8M | 4.3M | (2.1M) | (2.0M) | |
| Capital Stock | 7K | 16K | 17K | 20K | 24K | 16.9K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biocardia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biocardia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocardia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocardia Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.03) | Revenue Per Share 0.264 | Quarterly Revenue Growth (0.93) | Return On Assets (1.16) | Return On Equity (7.04) |
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biocardia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.